Director Finney Kevin purchases 166,668 shares across 6 transactions (Jul-Aug 2025) at blended $0.37, tripling stake to 204,771 shares
Director Kevin Finney executed 6 separate purchases totaling 166,668 shares for $61,933.84 over a five-week period, with prices ranging from $0.35 to $0.40. This action increased his holdings by 437.4%, from 38,103 shares to 204,771 shares. Vaxart is unprofitable (−$15.0M net income in latest full fiscal year) despite strong revenue growth of +288.9% year-over-year, and the stock trades at −62.6% from its 52-week high. The sustained accumulation at price points between $0.35 and $0.40 as the stock declined 16.0% over 30 days and 19.1% over 90 days demonstrates a director building a material position despite operational losses and downward price momentum. Investors should examine Vaxart's path to profitability and the catalyst (if any) that prompted this director-level capital deployment during a period of negative returns.